The foundation of TB Diagnostics

This patent describes a blood-based immune test that can tell the difference between active tuberculosis and latent infection by first “waking up” the immune system with TB antigens and then measuring a specific pattern of host biomarkers. After stimulating a patient’s sample with selected Mycobacterium tuberculosis antigens (such as Rv0081, TB18.2, and ESAT‑6/CFP‑10), the test reads out multiple cytokines and proteins (for example, IFN‑γ, IP‑10, IL‑6, CRP, and others) to generate a signature that indicates active disease versus latent TB. The approach improves on traditional tests by focusing on antigen-induced host responses rather than just detecting infection, enabling diagnosis even when sputum is hard to obtain and supporting development of point‑of‑care assays

This patent covers lab tests and kits that diagnose TB meningitis by measuring a small panel of biomarkers in cerebrospinal fluid or blood. In CSF, the test looks for myeloperoxidase (MPO) together with immune and vascular markers like IFN‑γ, sICAM‑1, VEGF‑A, and CXCL8 to produce a diagnostic signature for TBM. In blood, it uses a complementary panel—adipsin (complement factor D), Aβ42, and IL‑10—to support diagnosis when lumbar puncture is not possible or to aid triage. The invention also includes device and software implementations to run, interpret, and potentially guide treatment decisions based on these biomarker patterns.

This patent outlines a diagnostic test for TB meningitis that measures a small set of immune biomarkers in a patient’s fluid sample to confirm disease. By checking for elevated levels of at least two markers—such as IL‑13, VEGF, LL‑37, IL‑7, IL‑12p70, IFN‑γ, IL‑6, IL‑10, IP‑10, MIP‑1α, MIP‑1β, RANTES, or GM‑CSF—compared with non‑TBM controls, the method provides a clear signature consistent with TBM, enabling earlier, more accurate diagnosis than single‑marker approaches.

This patent describes a rapid fingerstick blood test that helps diagnose or rule out TB by measuring C‑reactive protein (CRP) together with one or more immune biomarkers such as SAA, IP‑10 (CXCL10), SAP, I‑309 (CCL1), MIG (CXCL9), or ferritin on a multiplex lateral flow strip. The sample is applied to capture agents on the strip, and signal is detected using advanced readers such as up‑converting phosphor technology to enable sensitive, quantitative results at the point of care. The kit integrates the assay, device, and workflow to deliver quick decisions from a capillary fingerstick, supporting triage and treatment pathways in low‑resource settings.

This patent presents a blood-based test for TB that measures complement component 4 (CC4) together with at least one partner biomarker—such as CC4b, procalcitonin, CCL1 (I‑309), apolipoprotein‑CIII, RANTES, or TNF‑α—to generate a diagnostic signal for tuberculosis. It also claims an integrated device, kit, and software to run the assay and interpret results, enabling streamlined point‑of‑care use and potential treatment guidance within the same platform.

This patent describes a method that uses a novel set of immune markers—for example, EGF, sCD40L, VEGF, IL-1α, MIP-1β, TGF-α, TNF-α, and IFN-γ—to reliably distinguish between latent TB infection and active TB disease by analyzing blood samples stimulated with TB antigens. By combining results from these biomarkers in specific mathematical models, the test can accurately classify patients with active TB, household contacts, or controls—even in settings where traditional tests lack specificity or sensitivity. The invention includes multiplex kits and assay devices to perform the analysis, dramatically speeding up TB triage and supporting higher diagnostic accuracy than single-marker approaches.